{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:42:18Z","timestamp":1767969738265,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merck Serono S.A. (Geneva, Switzerland), a business of Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11523-020-00768-0","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T10:02:52Z","timestamp":1605002572000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Selective Oral MEK1\/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct00982865","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jean-Pierre","family":"Delord","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Pages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Dinulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Leijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Scheuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Massimini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"768_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms20061483","volume":"20","author":"P Savoia","year":"2019","unstructured":"Savoia P, Fava P, Casoni F, Cremona O. Targeting the ERK signaling pathway in melanoma. Int J Mol Sci. 2019;20:1483.","journal-title":"Int J Mol Sci."},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2017.11.016","volume":"54","author":"R Imperial","year":"2019","unstructured":"Imperial R, Toor OM, Hussain A, Subramanian J, Masood A. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: its clinical implications. Semin Cancer Biol. 2019;54:14\u201328.","journal-title":"Semin Cancer Biol."},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindemann N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011\u201322.","journal-title":"Lancet Oncol."},{"key":"768_CR4","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/bcj.2013.1","volume":"3","author":"C Chang-Yew Leow","year":"2013","unstructured":"Chang-Yew Leow C, Gerondakis S, Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J. 2013;3:e105.","journal-title":"Blood Cancer J."},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1038\/bcj.2015.103","volume":"5","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, Pigneux A, DeAngelo DJ, Raffloux E, Delauney J, et al. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1\/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J. 2015;5:e375.","journal-title":"Blood Cancer J."},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10637-018-0600-2","volume":"36","author":"RS Finn","year":"2018","unstructured":"Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018;36:1037\u201343.","journal-title":"Invest New Drugs."},{"key":"768_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:435\u201345.","journal-title":"Lancet Oncol."},{"key":"768_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107\u201314.","journal-title":"N Engl J Med."},{"key":"768_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248\u201360.","journal-title":"Lancet Oncol."},{"key":"768_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med."},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28:1631\u20139.","journal-title":"Ann Oncol."},{"key":"768_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkav G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018a;19:603\u201315.","journal-title":"Lancet Oncol."},{"key":"768_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkav G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018b;19:1315\u201327.","journal-title":"Lancet Oncol."},{"key":"768_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2141.2010.08127.x","volume":"149","author":"K Kim","year":"2010","unstructured":"Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al. Blockade of the MEK\/ERK signaling cascade by AS703026, a novel selective MEK1\/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010;149:537\u201349.","journal-title":"Br J Haematol."},{"key":"768_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1158\/0008-5472.CAN-10-3058","volume":"71","author":"J Yoon","year":"2011","unstructured":"Yoon J, Koo KH, Choi KY. MEK1\/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011;71:445\u201353.","journal-title":"Cancer Res."},{"key":"768_CR16","doi-asserted-by":"publisher","unstructured":"Lebb\u00e9 C, Italiano A, Hou\u00e9d\u00e9 N, Awada A, Aftimos P, Lesimple T, et al. Selective oral MEK1\/2 inhibitor pimasertib in metastatic melanoma: anti-tumor activity in a phase I, dose-escalation trial. Target Oncol. https:\/\/doi.org\/10.1007\/s11523-020-00767-1","DOI":"10.1007\/s11523-020-00767-1"},{"key":"768_CR17","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/bjc.2015.144","volume":"112","author":"T Macarulla","year":"2015","unstructured":"Macarulla T, Cervantes A, Tabernero J, Rosell\u00f3 S, Van Cutsem E, Tejpar S, et al. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Br J Cancer. 2015;112:1874\u201381.","journal-title":"Br J Cancer."},{"key":"768_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br J Cancer. 2017;116:575\u201383.","journal-title":"Br J Cancer."},{"key":"768_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482\u20139.","journal-title":"J Clin Oncol."},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","volume":"13","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782\u20139.","journal-title":"Lancet Oncol."},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queriolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249\u201356.","journal-title":"Lancet Oncol."},{"key":"768_CR22","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491.","journal-title":"ESMO Open."},{"key":"768_CR23","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, et al. Clinical and morphologic characteristics of MEK inhibitor\u2013associated retinopathy. Ophthalmology. 2017;124:1788\u201398.","journal-title":"Ophthalmology"},{"key":"768_CR24","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bcp.13078","volume":"82","author":"O Von Richter","year":"2016","unstructured":"Von Richter O, Massimini G, Scheible H, Udvaros I, Johne A. Pimasertib, a selective oral MEK1\/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. Br J Clin Pharmacol. 2016;82:1498\u2013508.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 6","key":"768_CR25","first-page":"1136P","volume":"27","author":"C Lebbe","year":"2016","unstructured":"Lebbe C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, et al. Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover. Ann Oncol. 2016;27(Suppl 6):1136P.","journal-title":"Ann Oncol."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00768-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:01:37Z","timestamp":1628611297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00768-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"10 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Merck Serono S.A. (Geneva, Switzerland), an affiliate of Merck KGaA, Darmstadt, Germany. Representatives of Merck KGaA participated in the study design; the collection, analysis, and interpretation of the data; and the development and submission of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.-P. Delord has received consulting fees or honoraria from MSD, Bristol Myers Squibb, Novartis, Roche, and Genentech. A. Italiano has received research funding from AstraZeneca, Bayer, Chugai, Merck, MSD, Pharmamar, and Roche; consulting fees or honoraria from AstraZeneca, Bayer, Roche, and Springworks; and reimbursement for travel from AstraZeneca and Roche. A. Awada has received research funding from MSD and Roche and has participated on advisory boards for Roche, Lilly, Puma Technology, Pfizer, Eisai Europe, Genoscience Pharma, Merck, Sopa Diagnostics, Bayer, Clovis Oncology, and Daiichi-Sankyo and speaker bureaus for Lilly. C. Lebb\u00e9 has received research funding from Roche, MSD, Bristol Myers Squibb, and Novartis; reimbursement for travel from Bristol Myers Squibb; and has served on speaker bureaus for Roche, MSD, Bristol Myers Squibb, Novartis, Pierre Fabr\u00e9, and Sanofi. T. Lesimple has received research funding from Roche and reimbursement for travel or review activities from Bristol Myers Squibb, MSD, Novartis, and Pierre Fabr\u00e9 Oncology. J.H.M Schellens has received research funding from Debiopharm and is a shareholder and employee of Modra Pharmaceuticals BV. R. Kefford has received reimbursement for travel from Amgen. S. Faivre has received consulting fees or honoraria from Blueprint, Bristol Myers Squibb, Bayer, Ipsen, EMD Serono, MSD, and Roche. A. Schueler and G. Massimini are employees and shareholders of Merck KGaA, Darmstadt, Germany. E. Raymond has received consulting fees or honorarium from Genoscience Pharma and SCOR and is a shareholder of Genoscience Pharma and SCOR. P. Aftimos, N. Hou\u00e9d\u00e9, C. Pages, M. Dinulescu, S. Leijen, S. Rottey, V. Kruse, and C. Gomez-Roca have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Study concept: SF, GM, ER. Study design: SF, GM, ER, JHMS. Data acquisition: NH, CP, TL, SL, SR, VK, SF, PA, ER. Quality control of data and algorithms: NH, SR. Data analysis and interpretation: NH, TL, JHMS, SR, SF, PA, AS, GM, ER. Statistical analysis: AS. Manuscript preparation: TL, GM, ER. Manuscript editing: PA, JHMS, SR, SF, GM, ER. Manuscript review: J-PD, AI, AA, PA, NH, CL, CP, TL, MD, JHMS, SL, SR, VK, RK, SF, CG-R, AS, GM, ER.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck KGaA\u2019s Data Sharing Policy. All requests should be submitted in writing to Merck KGaA's data sharing portal (). When Merck KGaA has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavor to gain agreement to share data in response to requests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The protocol was approved and registered with the appropriate regulatory authorities, and the study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}